MX2024004569A - 1h-pirazolo[4,3-c]quinolinas sustituidas y metodos de preparacion y uso de estas. - Google Patents

1h-pirazolo[4,3-c]quinolinas sustituidas y metodos de preparacion y uso de estas.

Info

Publication number
MX2024004569A
MX2024004569A MX2024004569A MX2024004569A MX2024004569A MX 2024004569 A MX2024004569 A MX 2024004569A MX 2024004569 A MX2024004569 A MX 2024004569A MX 2024004569 A MX2024004569 A MX 2024004569A MX 2024004569 A MX2024004569 A MX 2024004569A
Authority
MX
Mexico
Prior art keywords
pyrazolo
preparation
methods
substituted quinolines
hpk1
Prior art date
Application number
MX2024004569A
Other languages
English (en)
Spanish (es)
Inventor
Alexandre Vasilievich Ivachtchenko
Alexei Pushechnikov
Vladislav Zenonovich Parchinsky
Nikolay Savchuk
Ruben Abagyan
Oleg Mitkin
Original Assignee
Lomond Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lomond Therapeutics Inc filed Critical Lomond Therapeutics Inc
Publication of MX2024004569A publication Critical patent/MX2024004569A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024004569A 2021-10-15 2022-10-03 1h-pirazolo[4,3-c]quinolinas sustituidas y metodos de preparacion y uso de estas. MX2024004569A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163256260P 2021-10-15 2021-10-15
PCT/US2022/045555 WO2023064133A1 (en) 2021-10-15 2022-10-03 SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF

Publications (1)

Publication Number Publication Date
MX2024004569A true MX2024004569A (es) 2024-04-30

Family

ID=85988576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004569A MX2024004569A (es) 2021-10-15 2022-10-03 1h-pirazolo[4,3-c]quinolinas sustituidas y metodos de preparacion y uso de estas.

Country Status (11)

Country Link
US (1) US20250011319A1 (enExample)
EP (1) EP4416146A4 (enExample)
JP (1) JP2024539633A (enExample)
KR (1) KR20240093606A (enExample)
CN (1) CN118076605A (enExample)
AU (1) AU2022364646B2 (enExample)
CA (1) CA3233233A1 (enExample)
MX (1) MX2024004569A (enExample)
TW (2) TWI863003B (enExample)
WO (1) WO2023064133A1 (enExample)
ZA (1) ZA202406375B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118666857B (zh) * 2024-06-26 2025-02-25 江西农业大学 一种喹啉类化合物及其在农用杀菌剂中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140031547A1 (en) * 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
ES2872555T3 (es) * 2015-06-25 2021-11-02 Univ Health Network Inhibidores de HPK1 y métodos de uso de los mismos
CA3129772A1 (en) * 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Bicyclic hpk1 inhibitors
EP4087843A1 (en) * 2020-01-10 2022-11-16 Incyte Corporation Tricyclic compounds as inhibitors of kras
CA3179692A1 (en) * 2020-04-16 2021-10-21 Incyte Corporation Fused tricyclic kras inhibitors

Also Published As

Publication number Publication date
AU2022364646A1 (en) 2024-03-28
EP4416146A1 (en) 2024-08-21
CN118076605A (zh) 2024-05-24
TW202317567A (zh) 2023-05-01
TWI863003B (zh) 2024-11-21
ZA202406375B (en) 2025-01-29
JP2024539633A (ja) 2024-10-29
KR20240093606A (ko) 2024-06-24
WO2023064133A1 (en) 2023-04-20
US20250011319A1 (en) 2025-01-09
CA3233233A1 (en) 2023-04-20
AU2022364646B2 (en) 2025-10-09
EP4416146A4 (en) 2025-11-05
TW202442645A (zh) 2024-11-01

Similar Documents

Publication Publication Date Title
Kee et al. Bone morphogenetic proteins induce germ cell differentiation from human embryonic stem cells
ATE331514T1 (de) Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase
EP4327827A3 (en) Amorphous kinase inhibitor formulations and methods of use thereof
PH12022500017A1 (en) PI3K-a INHIBITORS AND METHODS OF USE THEREOF
EA202091709A1 (ru) Ингибиторы днк-пк
EA201492176A1 (ru) Селективные ингибиторы pi3k дельта
TW200616632A (en) Compounds modulating c-kit activity and uses therefor
NO20076093L (no) Substituerte amidderivater som proteinkinaseinhibitorer
BR0013551A (pt) Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
DK1812440T3 (da) Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser
EA200870048A1 (ru) ГЕТЕРОАРИЛ-ЗЕМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
WO2021074620A9 (en) [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors
ATE330608T1 (de) Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
MX2023010087A (es) Derivados heterociclicos como inhibidores de cinasas jano.
DK1401413T3 (da) Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme
WO2006135649A3 (en) Aminoquinoline and aminoquinazoline kinase modulators
WO2022026902A3 (en) Chimeric proteins and methods of use for treatment of central nervous system disorders
MX2025011886A (es) Derivados biciclicos semisaturados y usos relacionados
TW200716118A (en) Aminopyrimidines as kinase modulators
Cohen et al. The role of FGF-signaling in early neural specification of human embryonic stem cells
ZA202406375B (en) Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof
EA200800015A1 (ru) Аминопиримидины в качестве модуляторов киназы
MX2023010083A (es) Derivados heterociclicos como inhibidores de cinasas jano.
HK20113541A1 (zh) 经取代的1h-吡唑并[4，3-c]喹啉、其制备方法及用途
HK20075235A1 (en) Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof